Jump Financial’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-46,848
Closed -$1.89M 2093
2026
Q1
$1.89M Buy
46,848
+28,632
+157% +$1.07M 0.03% 678
2025
Q4
$634K Buy
+18,216
New +$1.43M 0.01% 1190
2025
Q3
Sell
-4,374
Closed -$321K 1854
2025
Q2
$321K Buy
+4,374
New +$317K ﹤0.01% 1388
2025
Q1
Sell
-14,242
Closed -$718K 1645
2024
Q4
$718K Buy
+14,242
New +$746K 0.02% 910
2024
Q3
Sell
-20,715
Closed -$673K 1707
2024
Q2
$673K Sell
20,715
-14,703
-42% -$403K 0.01% 996
2024
Q1
$892K Sell
35,418
-13,808
-28% -$326K 0.02% 864
2023
Q4
$1.6M Buy
+49,226
New +$1.35M 0.05% 491
2023
Q3
Sell
-32,300
Closed -$719K 1903
2023
Q2
$719K Buy
+32,300
New +$743K 0.03% 853
2023
Q1
Sell
-81,389
Closed -$1.65M 1659
2022
Q4
$1.65M Buy
81,389
+9,489
+13% +$238K 0.09% 311
2022
Q3
$1.84M Sell
71,900
-20,806
-22% -$557K 0.07% 405
2022
Q2
$2.21M Buy
92,706
+49,494
+115% +$1.08M 0.09% 287
2022
Q1
$973K Buy
+43,212
New +$919K 0.04% 534
2021
Q4
Sell
-17,029
Closed -$335K 1430
2021
Q3
$335K Buy
+17,029
New +$356K 0.02% 614
2021
Q1
Sell
-28,752
Closed -$752K 990
2020
Q4
$752K Buy
+28,752
New +$606K 0.13% 247

Other funds holding CORT

Jump Financial's CORT Position: Q2 2026 in Review

Jump Financial sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 46,848 shares — an estimated $1.89M sold.

Jump Financial first reported a position in CORT in Q4 2020 and held it in 14 quarters. The position peaked at $2.21M in Q2 2022. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Jump Financial reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 46,848 Corcept Therapeutics shares in Q2 2026, an estimated $1.89M.
  • Jump Financial first reported a position in Corcept Therapeutics in Q4 2020 and held it in 14 quarters.
  • Jump Financial's Corcept Therapeutics position peaked at $2.21M in Q2 2022.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.